Explore the importance of clinical trials for ovarian cancer treatments, highlighting innovative therapies and the need for early patient access.
Video content is prompted by the following:
Approaches to Treatment, Sequencing, and Heavily Pretreated Patients With Novel Agents
Key Discussion Points:
Notable Insights:
“Reach out early. Once someone’s platinum resistant, make sure they’re tested for folate. Make sure they’re tested for HER2...make sure you’ve got molecular testing done by whatever platform you want to do.”
“Find a local friend that has trials open and just run things by them so we can get patients access to these medications that are actually working.”
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More